DelveInsight’s, “Hearing Los Pipeline Insight 2023” report provides comprehensive insights about 35+ companies and 45+ pipeline drugs in the Hearing Loss pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key takeaways from the Hearing Loss Pipeline Insight Report
Recent Development Activities in the Hearing Loss Treatment Landscape
Discover the recent advances in hearing loss treatment drugs @ Hearing Loss Pipeline Outlook Report
Hearing Loss Overview
Hearing loss is an extremely common medical condition, progressing in incidence and severity with age. The affected population is also vast, varying between neonates to elderly patients, and is nearly omnipresent in the 70+ age group. Normal hearing function involves sound waves arriving at the auricle, passing through the external auditory canal (EAC), causing a vibration of the tympanic membrane. Vibration is then transmitted via the ossicles (malleus, incus, stapes) to the cochlea. Subsequently, hair cells inside the cochlea stimulate the eighth cranial nerve that transfers the stimuli to the brain. Processing of crude sounds occurs in the higher cortices of the brain, and this includes the comprehension of language. Hearing loss can be conductive, sensorineural, or mixed.
Hearing Loss Pipeline Report
In the Hearing Loss report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hearing Loss collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Hearing Loss Emerging Drugs
PIPE 505: Pipeline Therapeutics
PIPE-505 is a gamma secretase inhibitor that targets two pathways associated with sensorineural hearing loss and audibility. Currently, the drug is in Phase I/II stage of Clinical trial evaluation for the treatment of Sensorineural Hearing Loss.
FX 322: Frequency Therapeutics
FX-322 is designed to treat the underlying cause of sensorineural hearing loss (SNHL) by regenerating sensory hair cells through activation of progenitor cells already present in the cochlea. Frequency’s lead asset FX-322 has shown the first-ever statistically significant and clinically meaningful hearing improvement signal in clinical trials. Three clinical studies in which a single dose of FX-322 was administered have shown hearing improvements in measures of speech perception. In addition, in all FX-322 studies, this drug candidate was observed to be well-tolerated with no serious drug-related adverse effects. FX-322 is currently in Phase II b study.
Arazasetron: Sensorion
Arazasetron (SENS-401), is a first-in-class drug candidate to treat Sudden Sensorineural Hearing Loss (SSNHL). It is aiming at treating or protecting against inner ear lesions that lead to nerve degeneration and sensory hair cell loss. It is protected by a solid intellectual property with two patent families.
Learn more about the emerging hearing loss pipeline therapies @ Hearing Loss Clinical Trials Analysis
Hearing Loss Therapeutics Assessment
There are approx. 35+ key companies which are developing the therapies for Hearing Loss. The companies which have their Hearing Loss drug candidates in the most advanced stage, i.e. phase II include, Frequency Therapeutics.
Hearing Loss Segmentation Assessment
The hearing loss pipeline report proffers an integral view of the hearing loss emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.
Find out more about hearing loss treatment drugs @ Hearing Loss Treatment Landscape
Scope of the Hearing Loss Pipeline Report
Table of Content
Key Questions
Current Treatment Scenario and Emerging Therapies:-
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/report-store/brucellosis-market